While few studies have investigated optimal phosphate targets in other FGF23 disorders, previous trials demonstrated clinical improvements upon achieving low-normophosphatemia in patients with both XLH and TIO [10–12, 14]. Here, FGF23 is linked to X-linked hypophosphatemia.